Friday, April 23, 2021 Daily Archives

How Capacitance Measurement Can Improve Viral Vector and Virus-Based Vaccine Production

With the increasing development of viral vector and virus-based vaccines, technologies that help to manufacture and scale up these types of vaccine quickly and cost-effectively have become more critical. By accessing this special report from Aditya Bhat, a capacitance technology expert at Aber Instruments, you will find out how in-line capacitance measurement can produce a detailed fingerprint of cell culture processes and how that can benefit vaccine production. From case studies involving baculovirus, AAV, and measles, you will discover why…

Successful biosimilar development requires an outsourcing partner with the right experience

Demand for biosimilars is expected to increase significantly in the coming years, particularly in the United States. Developing new biosimilar candidates is a challenging endeavor that requires partnerships with outsourcing partners that have deep protein science, analytics, and process engineering expertise. Avid Bioservices has successfully supported biosimilar development for nearly a decade and is further expanding its capacity to provide manufacturing services from the bench through larger-scale commercialization. Anticipating Strong Growth in Demand for Biosimilars The value of the global…

Autologous therapy firms should use tech to cut COGS, says expert

Autologous therapy developers should consider “turnkey” manufacturing systems and robotic arms to minimize costs and manual handling, says an expert. The medical benefits of patient-specific, autologous cell therapies are proven according to Greg Russotti, Century Therapeutics’ CTO who told BPI West attendees the challenge now is reducing the cost of making such products. “Autologous [therapies] are proven to make major differences in patients’ lives. And, you know, no one can say they’re cures yet, but in some cases they are…

Evotec to build $180m European biomanufacturing plant

Evotec is set to build its second biomanufacturing J.POD facility at Campus Curie in Toulouse, France. The French facility will be Evotec’s first commercial biomanufacturing plant in Europe, with construction expected to begin during the second half of this year and the site anticipated to be fully operational in 2023. The firm will receive up to €50 million ($60m) from the French government, the Occitanie Region, the Haute-Garonne prefecture, Bpifrance, and Toulouse Métropole. However, the total investment is currently calculated…

Pfizer mRNA risk paying off as it moves to make 3bn doses of COVID jab

Pfizer says it will produce 3 billion doses of its COVID-19 vaccine this year and will further invest in its manufacturing network to support continued global demand. Through its partnership with BioNTech, Pfizer became the first company to bring a messenger RNA-based product to market, namely the COVID-19 vaccine Comirnaty (BNT162b2). Last month, the firm estimated it was set to make around $15 billion from global sales of the vaccine this year, based on production projections of 2 billion doses.…